

1
2 **Adiponectin/leptin ratio - a marker of insulin sensitivity in pre-eclampsia and**
3 **fetal growth**

4 Victoria Elizabeth de Knecht^{1,2}, Paula L. Hedley^{1,3}, Anna K. Eltvedt¹, Sophie
5 Placing¹, Karen Wøjdemann⁴, Anne-Cathrine Shalmi⁵, Line Rode⁶, Jørgen
6 Kanters⁷, Karin Sundberg⁸, Ann Tabor^{8,9}, Ulrik Lausten-Thomsen¹⁰, Michael
7 Christiansen^{1,7*}

8
9 ¹Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark

10 ²Department of Paediatrics, University Hospital Slagelse, Slagelse, Denmark

11 ³Brazen Bio, Los Angeles, California, USA

12 ⁴Department of Gynecology and Obstetrics, Bornholm Hospital, Rønne, Denmark

13 ⁵Department of Obstetrics, Hillerød Hospital, Hillerød, Denmark

14 ⁶Department of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, Glostrup,
15 Denmark

16 ⁷Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

17 ⁸Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital
18 Rigshospitalet, Copenhagen, Denmark

19 ⁹Department of Clinical Medicine, Faculty of Medical and Health Sciences, University of
20 Copenhagen, Copenhagen, Denmark

21 ¹⁰Department of Neonatology, University Hospital Rigshospitalet, Copenhagen, Denmark

22
23
24

25

26 **Corresponding author:**

27 Michael Christiansen*, M.D., FRCPath

28 Department for Congenital Disorders

29 Statens Serum Institut

30 5 Artillerivej DK2300S

31 Copenhagen, Denmark

32 Telephone: +45 32683657; Fax: +45 32683878; E-mail: mic@ssi.dk

33

34 **Abstract**

35 The serum adiponectin-leptin ratio (A/L ratio) is a surrogate marker of insulin sensitivity.
36 Pre-eclampsia (PE) is associated with maternal metabolic syndrome and occasionally impaired
37 fetal growth. We assessed whether the A/L ratio in first-trimester maternal serum was associated
38 with PE and/or birth weight. Adiponectin and leptin were quantitated in first-trimester blood
39 samples (gestational week 10⁺³-13⁺⁶) from 126 women who later developed PE with proteinuria,
40 (98 mild PE; 21 severe PE; 7 HELLP syndrome), and 297 controls, recruited from the
41 Copenhagen First-Trimester Screening Study. The A/L ratio was reduced in PE pregnancies,
42 median 0.17 (IQR: 0.12-0.27) compared to controls, median 0.32 (IQR: 0.19-0.62), (p<0.001). A
43 multiple logistic regression showed that PE was negatively associated with A/L ratio independent
44 of maternal BMI (odds ratio = 0.08, 95% CI = 0.0322 to 0.214). Adiponectin (AUC = 0.632) and
45 PAPP-A (AUC = 0.605) were negatively, and leptin (AUC = 0.712) was positively associated
46 with PE. However, the A/L ratio was a better predictor of PE (AUC = 0.737). No significant
47 association was found between A/L ratio and clinical severity of pre-eclampsia or preterm birth.
48 PE was associated with significantly lower relative birth weight, (p<0.001). A significant
49 negative correlation was found between relative birth weight and A/L ratio in controls but not in
50 PE pregnancies, (β = -0.144, 95% CI = -9.944 to -0.093), independent of maternal BMI. After
51 correction for maternal BMI, leptin was significantly associated with relative birth weight, (β =
52 0.197, 95 % CI = 2.361 to 14.353), while adiponectin was not significantly associated. Our
53 findings suggest that an impairment of the A/L ratio (as seen in metabolic syndrome) in first-
54 trimester is characteristic of PE, while aberrant fetal growth in PE is not dependent on insulin
55 sensitivity but rather on leptin associated pathways.

56 **Word count:** 291

57

58 **Key words:** adipocytokine, adiponectin, birth weight, fetal growth restriction, leptin, metabolic

59 syndrome, placenta

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80 **Background**

81 Pre-eclampsia (PE) is a serious pregnancy complication characterized by high blood pressure and
82 proteinuria and/or impaired liver and kidney function, pulmonary edema, hematological
83 complications, seizures, or uteroplacental dysfunction (1,2). The prevalence of PE is 3-5% in the
84 western world and it is a major contributor to maternal and fetal/neonatal morbidity (1). In places
85 with limited access to healthcare, e.g. in large parts of Asia, Africa and South America, between
86 one-tenth and one-quarter of maternal deaths are associated with hypertensive disorders of
87 pregnancy (3). PE predisposes both mothers and offspring to a plethora of deleterious health
88 outcomes. Mothers have increased risk of developing hypertension and other cardiovascular
89 diseases (4), metabolic syndrome, and overweight and obesity years after pregnancy (5). Infants
90 too are at risk of developing cardiovascular disease (6), metabolic syndrome and overweight and
91 obesity later in life (6–8). The pathophysiological background of PE is elusive, but most likely
92 heterogeneous, involving uterine-placental dysangiogenesis, endothelial dysfunction,
93 immunological abnormalities, genetic factors, or metabolic disturbances (9).

94 Pregnancy requires major metabolic adaptations to ensure adequate nutrient supply for
95 the fetus (10). An important aspect of this is changes in maternal insulin sensitivity (IS) and
96 insulin resistance (IR) that is mediated by a range of maternal, placental, and fetal hormones
97 (11). First trimester is characterized by a relative increase in insulin sensitivity, needed to ensure
98 uptake of nutrients in the mother; this changes as insulin resistance develops during second-
99 trimester (12,13).

100

101 Pre-pregnancy IR is associated with the development of gestational diabetes mellitus
102 (GDM) (14), with ensuing risk of fetal over-nutrition and macrosomia (15–17) as well as PE
103 (18). Early-onset PE is frequently associated with fetal growth restriction (FGR) (19), while late-
104 onset PE is more often associated with macrosomia (2). Both fetal under- and over nutrition may
105 lead to changes in body composition in the fetus that persist after birth (20,21). These, in turn,
106 may lead to permanent metabolic alterations, epigenetic changes, and fetal programming, that
107 ultimately result in the development of metabolic syndrome and its associated diseases later in
108 life (6–8,22).

109
110 The risk of developing PE increases with increasing body mass index (BMI) (23).
111 Furthermore, adiponectin and leptin play a major role in the metabolic adaptations to pregnancy.
112 There is a small placental contribution to maternal leptin levels (24,25), but not to the extent that
113 it obviates the relation between maternal BMI and leptin. A number of hormonal factors regulate
114 the insulin signaling pathway and control the balance between IS and IR in order to
115 accommodate pregnancy (11) as well as compensate for the metabolic consequences of
116 overweight and obesity (26). Several hormones have been suggested to be involved in first-
117 trimester fetal growth, and placental growth hormone appears to be of particular significance
118 (27). In pregnant women with BMI values on the extreme ends of the scale, insufficient
119 homeostatic compensatory mechanisms may result in presentation of disease symptoms. This
120 process may be reflected in adipocytokine levels, already in first-trimester (26).

121
122 Adiponectin and leptin are involved in a wide range of physiological processes and seem
123 perturbed in GDM and PE (14,28–35). Serum adiponectin-leptin ratio (A/L ratio) is a surrogate

124 marker of IS that correlates well with signs of metabolic syndrome in childhood and adolescence
125 (36,37). It has been shown to correlate with insulin resistance in pregnancy (38). However, it has
126 not been associated with adverse pregnancy outcomes.

127 In this study, we use A/L ratio as a marker of IS and hypothesize that A/L ratio is
128 perturbed in the first-trimester of pregnancies that later develop PE. Furthermore, we assess the
129 significance of the A/L ratio for fetal growth, as maternal, placental, and fetal leptin have been
130 reported to contribute to intrauterine growth (24). Accordingly, this study examines the
131 relationship between first-trimester A/L ratio and PE as well as the relationship between
132 adiponectin, leptin, and A/L ratio and birth weight.

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147 **Materials and methods**

148

149 *Study design and participants*

150

151 This study is a case-control sub-study of the 1997 to 2001 Copenhagen First-Trimester Screening
152 Study focusing on screening for chromosomal disorders (39). Several sub-studies on fetal growth
153 (27), PE (25,40–42), and sources of Down syndrome serum marker variability (43,44) have been
154 performed. The adipocytokine data used were collected from 2003 to 2010 and stored in an
155 anonymized database. Only singleton pregnancies with first-trimester blood samples (gestational
156 age (GA) 10⁺³-13⁺⁶) were included. GA was determined by crown rump length (CRL). Selection
157 of cases and controls is described in Laigaard et al (40). Briefly, 126 pregnancies that developed
158 PE were selected for the study and 297 controls were matched with respect to maternal age,
159 parity, and GA at time of sampling (40). Of the 126 women with PE, 98 had mild PE, 21 had
160 severe PE, and seven had HELLP syndrome. Ten pregnancies ended in delivery before GA 34⁺⁰.
161 Regarding ethnicity, 93% of the women were of North European descent. Demographic and
162 clinical parameters are given in table 1.

163

164 *Data collection*

165

166 Detailed clinical information, as well as pregnancy-associated plasma protein A (PAPP-A) and
167 beta-chorionic gonadotropin (hCG β) concentrations, were collected as part of the Copenhagen
168 First-Trimester Screening Study, as previously described (39). PE pregnancies were categorized
169 into one of three severity groups: mild PE, severe PE, and HELLP syndrome as per criteria from

170 The International Society for the Study of Hypertension in Pregnancy (ISSHP) during the course
171 of the First-Trimester Screening Study (45). Briefly, PE was defined as persistent hypertension,
172 (either a systolic blood pressure ≥ 140 mm Hg or a diastolic blood pressure ≥ 90 mm Hg),
173 occurring after 20 weeks of gestation in a previously normotensive woman, in combination with
174 proteinuria, (≥ 0.3 g in a 24-hour urine collection or dipstick urine analysis of $\geq 1+$). Severe PE
175 was defined by a diastolic blood pressure > 110 mm Hg in combination with subjective symptoms
176 and/or abnormal laboratory findings. HELLP syndrome was defined by the presence of
177 hemolysis, elevated liver enzymes, and low platelets. Early PE was defined as a PE pregnancy
178 that resulted in delivery prior to GA 34⁺⁰.

179

180 *Biochemical measurements*

181

182 All blood samples were collected in dry containers and kept at 4° C for a maximum of 48 hours
183 until storage at -20° C. Adiponectin and leptin concentrations were measured *in singlo* following
184 appropriate sample dilution (25,26) using the Human Adiponectin Enzyme-Linked
185 Immunosorbent Assay (ELISA) development kit, Duo Set (DY1065), and the Human Leptin
186 ELISA development kit, Duo Set (DY398), R&D Systems, Minneapolis, USA. The functional
187 detection limits of the assays were 62.5 pg/ml (for adiponectin) and 31.25 pg/ml (for leptin).

188

189 Evaluation of pre-analytic variables demonstrated that both adiponectin and leptin were
190 stable for at least 48 hours at 23° C and 10 freeze-thaw cycles. The intra-assay and inter-assay
191 coefficients of variation were $< 5\%$ and $< 10\%$, respectively for adiponectin and leptin.

192

193 *Data analysis*

194

195 Birth weights corrected for GA, relative birth weight, were calculated using intrauterine growth
196 curves developed by Marsal et al. (46). Weight classifications small-for-gestational-age (SGA),
197 appropriate-for-gestational-age (AGA), and large-for-gestational-age (LGA) were calculated
198 using $\pm 24\%$ as the upper and lower limits of relative birth weight (46). A/L ratio was calculated
199 as $([\text{adiponectin}]/[\text{leptin}])/1000$. Data were analyzed using generalized linear models following
200 logarithmic transformation as appropriate. When necessary, non-parametric statistics were
201 employed. A PAPP-A value corrected for GA at time of sampling was calculated using multiples
202 of the median (MoM). MoM of logPAPP-A in both controls and PE pregnancies were calculated
203 by performing a regression analysis in the control pregnancies of \log_{10} PAPP-A on GA at time of
204 sampling. All analyses were conducted using IBM SPSS Statistics, Version 28.0; Armonk, NY:
205 IBM Corp.

206

207 *Ethics*

208

209 The Copenhagen First Trimester Study was approved by the Scientific Ethics Committee for
210 Copenhagen and Frederiksberg Counties (No. (KF) 01-288/97) and the Data Protection Agency
211 approved the study protocol. All participants gave written informed consent.

212

213

214

215

216 **Results**

217

218 *Comparison of PE and control pregnancies*

219

220 A/L ratio was lower in PE pregnancies, 0.17 (IQR: 0.12 – 0.27) than in controls, 0.32 (IQR: 0.19
221 – 0.62) ($p < 0.001$), (table 1). PAPP-A was significantly lower in PE pregnancies than controls,
222 ($p < 0.001$), (table 1). Furthermore, a significant association was found between A/L ratio and
223 PAPP-A (log transformed and controlled for GA at time of testing) in PE ($\beta = 1.432$, 95% CI =
224 0.057 to 2.807). hCG β concentrations were not significantly different between the two groups,
225 (table 1). Offspring of women with PE had a lower GA at birth and lower relative birth weight
226 compared to the control group, ($p < 0.001$), (table 1). A larger proportion of PE pregnancies
227 delivered SGA infants, 14.3% in PE vs. 2.0% in controls ($p < 0.001$), (table 1). Compared to
228 control pregnancies, women with PE had significantly higher BMI, ($p < 0.001$), (table 1). CRL
229 and nuchal translucency measurements did not differ significantly between PE pregnancies and
230 controls, (table 1). 74 % of PE deliveries were induced compared to 16% in controls, ($p < 0.001$).

231

232 A multiple logistic regression showed that PE was negatively associated with A/L ratio
233 independent of maternal BMI (odds ratio = 0.082, 95% CI = 0.032 to 0.214). Adiponectin (area
234 under the curve (AUC) = 0.632) and PAPP-A (AUC = 0.605) were negatively, and leptin (AUC
235 = 0.712) was positively associated with PE. However, the A/L ratio was a better predictor of PE
236 (AUC = 0.737), (figure 1).

237

238 *Comparison of mild PE, severe PE, and HELLP syndrome*

239

240 The demographic, clinical, and paraclinical characteristics of mild PE, severe PE, and HELLP
241 pregnancies are presented in table 2. There was no discernable difference between A/L ratios in
242 the different severity groups (figure 2). The proportion of early PE (<GA week 34) increased
243 with increasing severity of PE, ($p < 0.001$). There was no significant difference in relative birth
244 weight between severity groups. However, the proportion of SGA infants was greater in severe
245 PE and HELLP, ($p = 0.006$).

246

247 *Comparison of early and late PE*

248

249 Demographic, clinical, and paraclinical characteristics of early and late PE are presented in table
250 3. No significant difference in A/L ratio between early and late PE was found. More frequently
251 early PE pregnancies were classified as severe PE and HELLP syndrome compared with late PE
252 pregnancies, 80.0% and 17.2%, respectively, ($p < 0.001$). Early PE infants had a significantly
253 lower relative birth weight than late PE infants, ($p < 0.001$). There was a difference in size for GA
254 between early and late PE, where 80.0% were SGA in early PE and 8.6% were SGA in late PE,
255 ($p < 0.001$).

256

257 *Relative birth weight and A/L ratio*

258

259 A significant negative correlation was found between relative birth weight and A/L ratio in
260 controls but not in PE pregnancies, ($\beta = -0.144$, CI = -9.944 to -0.093). This was independent of
261 maternal BMI. The relationship was valid also when only considering AGA controls ($\beta = -0.189$,

262 95% CI = -10.370 to -1.439), again independent of maternal BMI. After correction for maternal
263 BMI, leptin was significantly associated with relative birth weight, ($\beta = 0.197$, 95% CI = 2.361 to
264 14.353), while adiponectin was not significantly associated. No association was found between
265 A/L ratio and CRL in either PE or control pregnancies, independent of maternal BMI.

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285 **Discussion**

286

287 In this study we showed, for the first time, that A/L ratio in first-trimester was significantly lower
288 in pregnancies that developed PE compared to controls. Previous studies have either not
289 examined first-trimester pregnancies (38,47,48) or examined the effect of A/L ratio in first-
290 trimester obese women who developed PE (26). In the latter study, a decrease in A/L ratio, albeit
291 insignificant, was found (26). A/L ratio was, however, associated with development of GDM in
292 the same cohort (49). This is compatible with the inverse correlation between A/L ratio and the
293 homeostasis model assessment of IR in pregnancy (38). The A/L ratio decreased with maternal
294 BMI, a known risk factor of PE (26), but the A/L ratio outperformed maternal BMI as a predictor
295 of PE.

296

297 The leptin/adiponectin ratio (a marker of insulin resistance) is associated with
298 cardiometabolic risk factors in children (36,37). Furthermore, in adults, a decreased A/L ratio has
299 been shown to be associated with IR in various metabolic disorders, including diabetes mellitus
300 (50,51), polycystic ovary syndrome (PCOS) (52–54), metabolic syndrome (55), atherosclerosis
301 (56) and obesity (57). The reduction in A/L ratio, thus, likely reflects increasing IR. This could
302 also explain the association between PE and PCOS (58).

303

304 In first-trimester PE pregnancies, the change in A/L ratio is driven by both a decrease in
305 adiponectin and an increase in leptin. Adiponectin is a protective factor against cardiometabolic
306 diseases (59), so the association between PE and later hypertension and diabetes type 2 could be
307 explained by this relation. Adiponectin is not synthesized by the placenta, so the changes in

308 adiponectin concentrations are the result of physiological changes in the mother. Leptin is partly
309 synthesized by the placenta and largely by adipose tissue in the mother (33). However, the effect
310 of leptin is modulated by the presence of soluble leptin receptor as well as variable expression of
311 leptin receptors in different tissues (60). As pregnancy requires metabolic adaptations through
312 gestation, mediated by several endocrine axes, the present study precludes a more precise
313 analysis of the causation of the changes in adiponectin and leptin.

314
315 The receiver operating characteristic (ROC) curve analysis showed that A/L ratio was a
316 better predictor of PE than leptin and adiponectin individually. However, the AUC of A/L ratio is
317 so small that it precludes a use of A/L ratio as a first-trimester single marker of later PE.
318 Likewise, PAPP-A is a marker for PE, but only used as a single marker in high risk pregnancies.
319 However, it is possible that A/L ratio might contribute to improving the efficiency and clinical
320 utility of either PE screening algorithms based on clinical information (61) or algorithms
321 including ultrasound and biochemical markers (62). An advantage of a biochemical marker that
322 may be measured on dried filter paper blood spots is that it may be used in populations with
323 challenged access to prenatal care. This might be of particular importance in low- and middle-
324 income countries.

325
326 There was no discernable difference between A/L ratios in the different severity groups of
327 PE or between early and late PE. Thus, the A/L ratio in first trimester cannot be used to discern
328 severity or early delivery in PE pregnancies. This suggests that IR predisposes to PE but other
329 factors determine clinical presentation. A significantly larger cohort of PE cases will be needed

330 to further investigate the performance of A/L ratio in early- and late-onset PE, severe PE and
331 HELLP. Samples that were few in number in the present study.

332
333 A significant positive association between PAPP-A - a known marker for PE, placental
334 dysfunction, and FGR - and A/L ratio was found in PE pregnancies. This is interesting as the
335 growth hormone – insulin-like growth factor (IGF) axis, where PAPP-A is a placenta-derived
336 insulin-like growth factor binding protein (IGFBP) -2, -4, and -5 protease (63), plays a major role
337 for both fetal and placental growth (possibly due to its importance for bioavailability of IGF)
338 (64). This specific finding needs to be confirmed through replication in other data sets.

339
340 A negative relationship between A/L ratio and relative birth weight was only found in
341 controls, suggesting that the homeostatic mechanisms involving adiponectin and leptin are
342 perturbed in PE. This finding was independent of maternal BMI. One explanation could,
343 however, be that 74% of PE pregnancies were induced, in contrast to 16% of controls. Thus, the
344 timing of parturition is for the majority of PE cases determined by the obstetrician, and not by
345 endocrine effector systems. The relationship between A/L ratio and relative birth weight was also
346 apparent when examining just AGA controls, indicating that it is not the extreme relative birth
347 weights driving the overall association. Interestingly, the association between A/L ratio and
348 relative birth weight in controls was driven by a positive association between leptin and relative
349 birth weight. Adiponectin did not contribute to this association. Thus, relative birth weight does
350 not seem to be dependent on IS but rather on leptin associated pathways (24).

351

352 Leptin contributed independently to the negative association between A/L ratio and
353 relative birth weight in controls. Leptin has a permissive role in several reproductive functions
354 (65), and in the current context, one might hypothesize that leptin reflects whether maternal
355 energy stores are sufficient sustain normal fetal growth. We know that the relationship between
356 leptin and maternal BMI is perturbed at high BMI levels (26), and increased IR originating from
357 adipose tissue can be a contributing factor (66).

358
359 PE is – in some cases - associated with reduced fetal size and as expected, we found that
360 women with PE had infants with significantly lower relative birth weight compared with
361 controls. Yet, interestingly, there was a lack of association between birth weight and A/L ratio in
362 PE pregnancies. These findings suggest that disturbances in metabolic homeostasis are already
363 apparent long before the development of PE symptoms, by definition in week 20, and have
364 negative consequences for fetal growth. Alternatively, the above mentioned large difference in
365 induction rates between PE pregnancies and controls may override the normal homeostatic
366 mechanisms controlling time of parturition. However, the period of relative IS and optimal
367 nutrient access in first-trimester may be reduced in women who develop PE as they instead risk
368 experiencing premature and/or increased IR. This possible shift between IS and IR already in
369 first-trimester may herald the PE associated impaired fetal growth.

370
371 Even though the study included a broad range of clinical parameters, some important
372 variables, such as gender of offspring and gestational weight gain during pregnancy were not
373 included. Another limitation of this study was that only total adiponectin levels were measured.

374 Three forms of adiponectin, low-, medium-, and high- molecular-weight (HMW) adiponectin
375 have been identified, where only HMW adiponectin has been shown to be associated to PE (67).

376

377 **Conclusions**

378

379 A reduced A/L ratio is a first-trimester characteristic of pregnancies that later develop PE.

380 However, neither severity nor time of onset was associated with A/L ratio. The A/L ratio,

381 reflecting IS, is a better discriminator between PE and controls than either leptin or adiponectin.

382 Relative birth weight was associated with A/L ratio, however, this was driven by leptin alone.

383 Changes in birth weight do not seem to be dependent on insulin sensitivity, as is the case for PE,

384 but rather on leptin associated pathways.

385

386 **Word count, manuscript: 3002**

387

388

389

390

391

392

393

394

395

396

397 **List of abbreviations:**

398

399 - AGA: appropriate-for-gestational-age

400 - A/L ratio: serum adiponectin-leptin ratio

401 - AUC: area under the curve

402 - BMI: body mass index

403 - CRL: crown rump length

404 - ELISA: enzyme-linked immunosorbent assay

405 - FGR: fetal growth restriction

406 - GA: gestational age

407 - GDM: gestational diabetes mellitus

408 - HCG β : beta-chorionic gonadotropin

409 - HMW: high molecular weight

410 - IGF: insulin-like growth factor

411 - IGFBP: insulin-like growth factor binding protein

412 - IR: insulin resistance

413 - IS: insulin sensitivity

414 - ISSHP: The International Society for the Study of Hypertension

415 - LGA: large-for-gestational-age

416 - MoM: multiple of the median

417 - PAPP-A: pregnancy-associated plasma protein A

418 - PCOS: polycystic ovary syndrome

419 - PE: pre-eclampsia

420 - ROC: receiver operating characteristic

421 - SGA: small-for-gestational-age

422

423 **Declarations**

424

425 *Ethics approval and consent to participate:* The study was a sub-study of the Copenhagen First-
426 Trimester Screening Study, which was approved by the Scientific Ethics Committee for
427 Copenhagen and Frederiksberg Counties (No. (KF) 01-288/97). All participants gave written
428 informed consent.

429

430 *Consent for publication:* Not applicable.

431

432 *Availability of data and materials:* The datasets generated and/or analyzed during the current
433 study are not publicly available due to restrictions in handling personal data, and particularly
434 because participants were recruited at a time when it was not standard practice to make
435 samples/data publicly available but are available from the corresponding author on reasonable
436 request.

437

438 *Competing interests:* The authors declare that they have no competing interests.

439

440 *Funding:* The study received no external funding.

441

442 *Authors' contributions:* VK, MC, PH, and UL conceived and designed the sub-study; SP, KW,
443 ACS, LR, KS, and AT collected the data and performed clinical assessments; VK, MC, and PH
444 did the data analysis; VK, MC, PH, UL, AKE, LR, AT, and JK interpreted the results of the data;
445 VK, MC, PH, and UL drafted the work; all authors revised the work critically for intellectual
446 content; all authors approved the final version of the work to be published; all authors are
447 accountable for all aspects of the work in ensuring that questions related to the accuracy or
448 integrity of any part of the work are appropriately investigated and resolved.

449
450 *Acknowledgements:* We gratefully acknowledge the expert technical assistance of Pia Lind and
451 Pernilla Rasmussen. We also gratefully acknowledge the financial support to the Copenhagen
452 First Trimester Study from the Danish Medical Research Council, Copenhagen University, The
453 John and Birthe Meyer Foundation, The Ivan Nielsen Foundation, The Else and Mogens Wedell-
454 Wedellsborg Foundation, The Dagmar Marshall Foundation, The Egmont Foundation, The Fetal
455 Medicine Foundation, The Augustinus Foundation, The Gangsted Foundation, The A.P. Møller
456 Foundation, The Mads Clausens Foundation, The Copenhagen Hospital Corporation, and SAFE
457 Network of Excellence. This research has been conducted using the Danish National Biobank
458 resource, funded by the Novo Nordisk Foundation.

459

460

461

462

463

464

465 **References**

- 466
467
468 1. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-
469 eclampsia. *Lancet*. 2016 Mar 5;387(10022):999–1011.
- 470 2. Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. *N Engl J Med*. 2022 May
471 12;386(19):1817–32.
- 472 3. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia
473 [Internet]. Geneva: World Health Organization; 2011 [cited 2020 Jun 3]. (WHO Guidelines
474 Approved by the Guidelines Review Committee). Available from:
475 <http://www.ncbi.nlm.nih.gov/books/NBK140561/>
- 476 4. Hauspurg A, Countouris ME, Catov JM. Hypertensive Disorders of Pregnancy and Future
477 Maternal Health: How Can the Evidence Guide Postpartum Management? *Curr Hypertens*
478 *Rep*. 2019 Nov 27;21(12):96.
- 479 5. Alonso-Ventura V, Li Y, Pasupuleti V, Roman YM, Hernandez AV, Pérez-López FR.
480 Effects of preeclampsia and eclampsia on maternal metabolic and biochemical outcomes in
481 later life: a systematic review and meta-analysis. *Metab Clin Exp*. 2020 Jan;102:154012.
- 482 6. Karatza AA, Dimitriou G. Preeclampsia emerging as a novel risk factor for cardiovascular
483 disease in the offspring. *Curr Pediatr Rev*. 2019 Dec 23;
- 484 7. Goffin SM, Derraik JGB, Groom KM, Cutfield WS. Maternal pre-eclampsia and long-term
485 offspring health: Is there a shadow cast? *Pregnancy Hypertens*. 2018 Apr;12:11–5.
- 486 8. Pinheiro TV, Brunetto S, Ramos JGL, Bernardi JR, Goldani MZ. Hypertensive disorders
487 during pregnancy and health outcomes in the offspring: a systematic review. *J Dev Orig*
488 *Health Dis*. 2016;7(4):391–407.
- 489 9. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and
490 clinical implications. *BMJ*. 2019 15;366:l2381.
- 491 10. Mouzon SH de, Lassance L. Endocrine and metabolic adaptations to pregnancy; impact of
492 obesity. *Horm Mol Biol Clin Investig*. 2015 Oct;24(1):65–72.
- 493 11. Sonagra AD, Biradar SM, K D, Murthy D S J. Normal pregnancy- a state of insulin
494 resistance. *J Clin Diagn Res*. 2014 Nov;8(11):CC01-03.
- 495 12. Catalano PM, Roman-Drago NM, Amini SB, Sims EA. Longitudinal changes in body
496 composition and energy balance in lean women with normal and abnormal glucose tolerance
497 during pregnancy. *Am J Obstet Gynecol*. 1998 Jul;179(1):156–65.

- 498 13. García-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin
499 requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of
500 direction. *Diabetologia*. 2010 Mar;53(3):446–51.
- 501 14. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of
502 Gestational Diabetes Mellitus. *Int J Mol Sci*. 2018 Oct 26;19(11).
- 503 15. Brunner S, Schmid D, Hüttinger K, Much D, Heimberg E, Sedlmeier EM, et al. Maternal
504 insulin resistance, triglycerides and cord blood insulin in relation to post-natal weight
505 trajectories and body composition in the offspring up to 2 years. *Diabet Med*. 2013
506 Dec;30(12):1500–7.
- 507 16. Crume TL, Shapiro AL, Brinton JT, Glueck DH, Martinez M, Kohn M, et al. Maternal fuels
508 and metabolic measures during pregnancy and neonatal body composition: the healthy start
509 study. *J Clin Endocrinol Metab*. 2015 Apr;100(4):1672–80.
- 510 17. Shapiro ALB, Schmiege SJ, Brinton JT, Glueck D, Crume TL, Friedman JE, et al. Testing
511 the fuel-mediated hypothesis: maternal insulin resistance and glucose mediate the association
512 between maternal and neonatal adiposity, the Healthy Start study. *Diabetologia*. 2015
513 May;58(5):937–41.
- 514 18. Cho GJ, Park JH, Shin SA, Oh MJ, Seo HS. Metabolic syndrome in the non-pregnant state is
515 associated with the development of preeclampsia. *Int J Cardiol*. 2016 Jan 15;203:982–6.
- 516 19. Audette MC, Kingdom JC. Screening for fetal growth restriction and placental insufficiency.
517 *Semin Fetal Neonatal Med*. 2018;23(2):119–25.
- 518 20. Dessì A, Puddu M, Ottonello G, Fanos V. Metabolomics and fetal-neonatal nutrition:
519 between “not enough” and “too much.” *Molecules*. 2013 Sep 25;18(10):11724–32.
- 520 21. Hales CN, Barker DJ. The thrifty phenotype hypothesis. *Br Med Bull*. 2001;60:5–20.
- 521 22. Maiorana A, Del Bianco C, Cianfarani S. Adipose Tissue: A Metabolic Regulator. Potential
522 Implications for the Metabolic Outcome of Subjects Born Small for Gestational Age (SGA).
523 *Rev Diabet Stud*. 2007;4(3):134–46.
- 524 23. Motedayen M, Rafiei M, Rezaei Tavirani M, Sayehmiri K, Dousti M. The relationship
525 between body mass index and preeclampsia: A systematic review and meta-analysis. *Int J*
526 *Reprod Biomed (Yazd)*. 2019 Jul;17(7):463–72.
- 527 24. de Kneegt VE, Hedley PL, Kanters JK, Thagaard IN, Krebs L, Christiansen M, et al. The Role
528 of Leptin in Fetal Growth during Pre-Eclampsia. *Int J Mol Sci*. 2021 Apr 27;22(9).
- 529 25. Hedley PL, Placing S, Wøjdemann K, Carlsen AL, Shalmi AC, Sundberg K, et al. Free leptin
530 index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia. *Prenat*
531 *Diagn*. 2010 Feb;30(2):103–9.

- 532 26. Thagaard IN, Hedley PL, Holm JC, Lange T, Larsen T, Krebs L, et al. Leptin and
533 Adiponectin as markers for preeclampsia in obese pregnant women, a cohort study.
534 *Pregnancy Hypertens.* 2019 Jan;15:78–83.
- 535 27. Pedersen NG, Juul A, Christiansen M, Wøjdemann KR, Tabor A. Maternal serum placental
536 growth hormone, but not human placental lactogen or insulin growth factor-1, is positively
537 associated with fetal growth in the first half of pregnancy. *Ultrasound Obstet Gynecol.* 2010
538 Nov;36(5):534–41.
- 539 28. Retnakaran A, Retnakaran R. Adiponectin in pregnancy: implications for health and disease.
540 *Curr Med Chem.* 2012;19(32):5444–50.
- 541 29. Herrid M, Palanisamy SKA, Ciller UA, Fan R, Moens P, Smart NA, et al. An updated view
542 of leptin on implantation and pregnancy: a review. *Physiol Res.* 2014;63(5):543–57.
- 543 30. Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipokines in gestational
544 diabetes mellitus and pre-eclampsia. *Clin Endocrinol (Oxf).* 2012 Jan;76(1):2–11.
- 545 31. Dos Santos E, Duval F, Vialard F, Dieudonné MN. The roles of leptin and adiponectin at the
546 fetal-maternal interface in humans. *Horm Mol Biol Clin Investig.* 2015 Oct;24(1):47–63.
- 547 32. Hauguel-de Mouzon S, Lepercq J, Catalano P. The known and unknown of leptin in
548 pregnancy. *Am J Obstet Gynecol.* 2006 Jun;194(6):1537–45.
- 549 33. D’Ippolito S, Tersigni C, Scambia G, Di Simone N. Adipokines, an adipose tissue and
550 placental product with biological functions during pregnancy. *Biofactors.* 2012
551 Feb;38(1):14–23.
- 552 34. Pérez-Pérez A, Toro A, Vilariño-García T, Maymó J, Guadix P, Dueñas JL, et al. Leptin
553 action in normal and pathological pregnancies. *J Cell Mol Med.* 2018;22(2):716–27.
- 554 35. Dalamaga M, Srinivas SK, Elovitz MA, Chamberland J, Mantzoros CS. Serum adiponectin
555 and leptin in relation to risk for preeclampsia: results from a large case-control study. *Metab*
556 *Clin Exp.* 2011 Nov;60(11):1539–44.
- 557 36. Frithioff-Bøjsøe C, Lund MAV, Lausten-Thomsen U, Hedley PL, Pedersen O, Christiansen
558 M, et al. Leptin, adiponectin, and their ratio as markers of insulin resistance and
559 cardiometabolic risk in childhood obesity. *Pediatr Diabetes.* 2020 Mar;21(2):194–202.
- 560 37. Lausten-Thomsen U, Lund MAV, Frithioff-Bøjsøe C, Hedley PL, Pedersen O, Hansen T, et
561 al. Reference values for leptin/adiponectin ratio in healthy children and adolescents. *Clin*
562 *Chim Acta.* 2019 Jun;493:123–8.
- 563 38. Skvarca A, Tomazic M, Blagus R, Krhin B, Janez A. Adiponectin/leptin ratio and insulin
564 resistance in pregnancy. *J Int Med Res.* 2013 Feb;41(1):123–8.
- 565 39. Wøjdemann KR, Shalmi AC, Christiansen M, Larsen SO, Sundberg K, Brocks V, et al.
566 Improved first-trimester Down syndrome screening performance by lowering the false-

- 567 positive rate: a prospective study of 9941 low-risk women. *Ultrasound Obstet Gynecol.* 2005
568 Mar;25(3):227–33.
- 569 40. Laigaard J, Sørensen T, Placing S, Holck P, Fröhlich C, Wøjdemann KR, et al. Reduction of
570 the disintegrin and metalloprotease ADAM12 in preeclampsia. *Obstet Gynecol.* 2005
571 Jul;106(1):144–9.
- 572 41. De Villiers CP, Hedley PL, Placing S, Wøjdemann KR, Shalmi AC, Carlsen AL, et al.
573 Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first
574 trimester maternal serum screening for severe and early preeclampsia. *Clin Chem Lab Med.*
575 2017 Nov 27;56(1):65–74.
- 576 42. Christiansen M, Hedley PL, Placing S, Wøjdemann KR, Carlsen AL, Jørgensen JM, et al.
577 Maternal Serum Resistin Is Reduced in First Trimester Preeclampsia Pregnancies and Is a
578 Marker of Clinical Severity. *Hypertens Pregnancy.* 2015 Nov;34(4):422–33.
- 579 43. Laigaard J, Larsen SO, Pedersen NG, Hedley PL, Gjerris AC, Wøjdemann KR, et al. ADAM
580 12-S in first trimester: fetal gender, smoking and maternal age influence the maternal serum
581 concentration. *Prenat Diagn.* 2009 May;29(5):525–7.
- 582 44. Laigaard J, Pedersen NG, Larsen SO, Hedley PL, Wøjdemann K, Gjerris AC, et al.
583 ADAM12 in first trimester maternal serum from pregnancies conceived by assisted
584 reproduction techniques (ART). *Prenat Diagn.* 2009 Jun;29(6):628–9.
- 585 45. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification
586 and diagnosis of the hypertensive disorders of pregnancy: statement from the International
587 Society for the Study of Hypertension in Pregnancy (ISSHP). *Hypertens Pregnancy.*
588 2001;20(1):IX–XIV.
- 589 46. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves
590 based on ultrasonically estimated foetal weights. *Acta Paediatr.* 1996 Jul;85(7):843–8.
- 591 47. Nakatsukasa H, Masuyama H, Takamoto N, Hiramatsu Y. Circulating leptin and angiogenic
592 factors in preeclampsia patients. *Endocr J.* 2008 Jul;55(3):565–73.
- 593 48. Ouyang Y, Chen H, Chen H. Reduced plasma adiponectin and elevated leptin in pre-
594 eclampsia. *Int J Gynaecol Obstet.* 2007 Aug;98(2):110–4.
- 595 49. Thagaard IN, Krebs L, Holm JC, Lange T, Larsen T, Christiansen M. Adiponectin and leptin
596 as first trimester markers for gestational diabetes mellitus: a cohort study. *Clin Chem Lab*
597 *Med.* 2017 Oct 26;55(11):1805–12.
- 598 50. Zaletel J, Barlovic DP, Prezelj J. Adiponectin-leptin ratio: a useful estimate of insulin
599 resistance in patients with Type 2 diabetes. *J Endocrinol Invest.* 2010 Sep;33(8):514–8.
- 600 51. Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-
601 leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. *Metab Clin*
602 *Exp.* 2005 Mar;54(3):281–6.

- 603 52. Obirikorang C, Owiredu WKBA, Adu-Afram S, Acheampong E, Asamoah EA, Antwi-
604 Boasiakoh EK, et al. Assessing the variability and predictability of adipokines (adiponectin,
605 leptin, resistin and their ratios) in non-obese and obese women with anovulatory polycystic
606 ovary syndrome. *BMC Res Notes*. 2019 Aug 15;12(1):513.
- 607 53. Sarray S, Madan S, Saleh LR, Mahmoud N, Almawi WY. Validity of adiponectin-to-leptin
608 and adiponectin-to-resistin ratios as predictors of polycystic ovary syndrome. *Fertil Steril*.
609 2015 Aug;104(2):460–6.
- 610 54. Svendsen PF, Christiansen M, Hedley PL, Nilas L, Pedersen SB, Madsbad S. Adipose
611 expression of adipocytokines in women with polycystic ovary syndrome. *Fertil Steril*. 2012
612 Jul;98(1):235–41.
- 613 55. Mirza S, Qu HQ, Li Q, Martinez PJ, Rentfro AR, McCormick JB, et al. Adiponectin/leptin
614 ratio and metabolic syndrome in a Mexican American population. *Clin Invest Med*. 2011 Oct
615 1;34(5):E290.
- 616 56. Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A
617 promising index to estimate adipose tissue dysfunction. Relation with obesity-associated
618 cardiometabolic risk. *Adipocyte*. 2018 02;7(1):57–62.
- 619 57. Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Adiponectin-
620 leptin Ratio is a Functional Biomarker of Adipose Tissue Inflammation. *Nutrients*. 2019 Feb
621 22;11(2).
- 622 58. Naver KV, Grinsted J, Larsen SO, Hedley PL, Jørgensen FS, Christiansen M, et al. Increased
623 risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and
624 hyperandrogenaemia. *BJOG*. 2014 Apr;121(5):575–81.
- 625 59. Younus S, Rodgers G. Biomarkers associated with cardiometabolic risk in obesity. *Am Heart*
626 *Hosp J*. 2011;9(1):E28-32.
- 627 60. Fasshauer M, Blüher M. Adipokines in health and disease. *Trends Pharmacol Sci*. 2015
628 Jul;36(7):461–70.
- 629 61. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet*
630 *Gynecol*. 2020 Jun;135(6):e237–60.
- 631 62. Chaemsaitong P, Sahota DS, Poon LC. First trimester preeclampsia screening and
632 prediction. *Am J Obstet Gynecol*. 2022 Feb;226(2S):S1071-S1097.e2.
- 633 63. Steffensen LB, Conover CA, Oxvig C. PAPP-A and the IGF system in atherosclerosis:
634 what's up, what's down? *Am J Physiol Heart Circ Physiol*. 2019 Nov 1;317(5):H1039–49.
- 635 64. Kaur H, Muhlhausler BS, Roberts CT, Gatford KL. The growth hormone-insulin like growth
636 factor axis in pregnancy. *J Endocrinol*. 2021 Sep 1;JOE-21-0087.R1.

- 637 65. Childs GV, Odle AK, MacNicol MC, MacNicol AM. The Importance of Leptin to
638 Reproduction. *Endocrinology*. 2021 Feb 1;162(2).
- 639 66. Spradley FT. Metabolic abnormalities and obesity's impact on the risk for developing
640 preeclampsia. *Am J Physiol Regul Integr Comp Physiol*. 2017 Jan 1;312(1):R5–12.
- 641 67. Takemura Y, Osuga Y, Koga K, Tajima T, Hirota Y, Hirata T, et al. Selective increase in
642 high molecular weight adiponectin concentration in serum of women with preeclampsia. *J*
643 *Reprod Immunol*. 2007 Feb;73(1):60–5.

644
645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663 **Tables and figures**

664

665 **Table 1.** Demographic and clinical characteristics of PE and control pregnancies

Parameter	PE (n=126)	Controls (n=297)	p-value
Maternal BMI (kg/m ²), median (IQR)	24.0 (21.7-26.4)	21.7 (20.1-24.0)	<0.001
GA at birth (days), median (IQR)	275.5 (263.8-283.0)	284.0 (278.0-290.0)	<0.001
GA below 34+0 weeks , n (%)	10 (7.9)	0 (0.0)	<0.001
Crown rump length (mm), median (IQR)	67.00 (61.0-72.0)	67.0 (61.0-74.0)	0.54
Relative birth weight (%), mean (\pm SD)	91.39 (\pm 14.98)	98.42 (\pm 11.89)	<0.001
Weight classification , n (%)			<0.001
- SGA	18 (14.3)	6 (2.0)	
- AGA	104 (82.5)	284 (95.6)	
- LGA	4 (3.2)	7 (2.4)	
Nuchal translucency (mm), median (IQR)	1.6 (1.3-1.9)	1.5 (1.3-1.9)	0.51
GA at time of sampling (days), median (IQR)	90.5 (87.0-93.0)	90.0 (87.5-94.0)	0.63
A/L ratio , median (IQR)	0.17 (0.12-0.27)	0.32 (0.19-0.62)	<0.001
PAPP-A (mIU/L), median (IQR)	3064.0 (1941.3-4579.8)	3874.0 (2582.5-5979.5)	<0.001
HCGβ (IU/L), median (IQR)	42.4 (28.1-59.2)	41.8 (26.9-63.1)	0.94

666 Abbreviations: AGA: appropriate-for gestational-age; A/L ratio: serum adiponectin-leptin ratio; BMI: body mass
667 index; GA: gestational age; HCG β : beta-chorionic gonadotropin; LGA: large-for-gestational-age; MoM: multiple of
668 the median; PAPP-A: pregnancy-associated plasma protein A; SGA: small-for-gestational-age
669

670

671

672 **Table 2.** Demographic, clinical, and paraclinical characteristics of mild PE, severe PE and
673 HELLP pregnancies
674

Parameter	Mild (n=98)	Severe (n=21)	HELLP (n=7)	p-value
Maternal BMI (kg/m ²), median (IQR)	24.0 (21.6-27.2)	24.5 (22.4-26.1)	23.1 (21.9-26.7)	0.76
GA at birth (days), median (IQR)	278.0 (269.0-284.0)	264.0 (238.5-275.5)	254.0 (216.0-276.0)	<0.001
GA <34+0 , n (%)	2 (2.0)	5 (23.8)	3 (42.9)	<0.001
Crown rump length (mm), mean (±SD)	66.0 (±8.96)	68.9 (±8.67)	67.9 (±4.60)	0.37
Actual birth weight (g), median (IQR)	3295.0 (2899.0-3700.0)	2682.0 (1850.0-3255.0)	1629.0 (1475.0-3400.0)	0.002
Relative birth weight (%), mean (±SD)	92.8 (±13.91)	88.3 (±17.19)	80.5 (±18.82)	0.06
Weight classification , n (%)				0.02
- SGA	9 (9.2)	6 (28.6)	3 (42.9)	
- AGA	86 (87.8)	14 (66.7)	4 (57.1)	
- LGA	3 (3.1)	1 (4.8)	0 (0.0)	
Nuchal translucency (mm), mean (±SD)	1.6 (±0.49)	1.7 (±0.52)	1.3 (±0.36)	0.22
GA at time of sampling (days), median (IQR)	90.0 (86.0-93.0)	91.0 (88.5-94.0)	91.0 (90.0-92.0)	0.33
A/L ratio , median (IQR)	0.16 (0.11-0.26)	0.17 (0.13-0.24)	0.25 (0.07-0.37)	0.63
PAPP-A (mIU/L), median (IQR)	3260.5 (2341.0-5077.8)	2350.0 (1650.0-4427.5)	2283.0 (1753.0-2607.0)	0.08
HCGβ (IU/L), median (IQR)	43.1 (30.4-63.3)	31.2 (17.1-50.6)	43.2 (26.4-84.4)	0.17

675 Abbreviations: AGA: appropriate-for-gestational-age; A/L ratio: serum adiponectin-leptin ratio; BMI: body mass
676 index; GA: gestational age; HCGβ: beta-chorionic gonadotropin; LGA: large-for-gestational-age; MoM: multiple of
677 the median; PAPP-A: pregnancy-associated plasma protein A; SGA: small-for-gestational-age;

678
679
680
681
682
683
684

685 **Table 3.** Demographic, clinical, and paraclinical characteristics of early and late PE


Parameter	Early PE (n=10)	Late PE (n=116)	p-value
Maternal BMI (kg/m ²), median (IQR)	25.6 (23.0-28.8)	24.0 (21.6-26.3)	0.20
GA at birth (days), median (IQR)	210.5 (201.0-229.8)	276.0 (268.0-283.8)	<0.001
PE severity , n (%)			<0.001
- Mild	2 (20.0)	96 (82.8)	
- Severe	5 (50.0)	16 (13.8)	
- HELLP	3 (30.0)	4 (3.4)	
Crown rump length (mm), median (IQR)	69.5 (62.3-72.3)	67.0 (60.3-72.0)	0.41
Relative birth weight (%), mean (\pm SD)	70.2 (\pm 6.79)	93.2 (\pm 14.07)	<0.001
Weight classification , n (%)			<0.001
- SGA	8 (80.0)	10 (8.6)	
- AGA	2 (20.0)	102 (87.9)	
- LGA	0 (0.0)	4 (3.4)	
Nuchal translucency (mm), median (IQR)	1.7 (1.4-1.8)	1.5 (1.3-1.9)	0.98
GA at time of sampling (days), median (IQR)	90.5 (87.5-93.0)	90.5 (87.0-93.0)	0.85
A/L ratio , median (IQR)	0.13 (0.11-0.25)	0.17 (0.12-0.27)	0.45
PAPP-A (mIU/L), median (IQR)	1761.0 (1470.0-2194.3)	3239.5 (2291.5-5019.8)	0.003
HCGβ (IU/L), median (IQR)	42.4 (28.1-59.2)	42.4 (29.6-61.9)	0.21

687 *Abbreviations: AGA: appropriate for gestational age; A/L ratio: serum adiponectin-leptin ratio; BMI: body mass*
688 *index; GA: gestational age; HCG β : beta-chorionic gonadotropin; LGA: large for gestational age; MoM: multiple of*
689 *the median; PAPP-A: pregnancy-associated plasma protein A; PE: pre-eclampsia; SGA: small for gestational age*
690

691

692 **Figure 1.** ROC curves of adiponectin, leptin, PAPP-A, and A/L ratio. A/L ratio was a better

693 predictor of PE compared to adiponectin, leptin, and PAPP-A.



694

695

696

697

698

699

700


701

702

703

704 **Figure 2.** Box-plot of A/L ratio in controls, mild PE, severe PE, and HELLP. There was no

705 discernable difference between A/L ratios in the different severity groups.



706